FDA approves Rhapsido (remibrutinib) for adults with symptomatic dermographism beyond CSU. Get the full details on this newly ...
Paris-based Rivercell raises $25M seed led by HV to build its AI Virtual Cell model that predicts how human cells respond to drugs. Explore how it works.
The TAURUS-1980 Phase I study has dosed its first participants, testing AV-1980R as a preventive tau vaccine. Read what researchers will assess next.
Tempus expands its collaboration with Moderna and Merck to support potential commercialization of a personalized cancer ...
Ultragenyx agreed to sell a rare pediatric disease priority review voucher for $210 million after GENGLYCOS approval. Explore ...
AmyriAD Therapeutics acquires Recognify Life Sciences in an all-share deal to gain RL-007 (inidascamine), a pro-cognitive candidate. Read full details.
Viatris agrees to acquire Pacira BioSciences in a $1.65B all-cash deal at $36.50 per share. Read how this non-opioid pain ...
Biohaven grants Ono Pharma exclusive rights to its MoDE pan-IgG degrader portfolio in Japan and Asia, with $80M upfront. Read the full deal details now.
The FDA approved Pfizer's Tukysa with trastuzumab and pertuzumab for HER2-positive breast cancer maintenance. Find out what ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results